Screening for Renal Complications in Children & Young Adults With Major

Status Not yet recruiting

Clinical Trial Summary

Sickle cell disease is the subject of targeted neonatal screening (carried out when one of the two parents is from an endemic country - sub-Saharan Africa, South-East Asia, Central America, the Caribbean) during the Guthrie test. Haemolysis, which results from the abnormality of the haemoglobin, and the vascular activation it causes, are responsible for multiple organ damage. Major sickle cell syndromes (MSC), by several mechanisms, are responsible for a wide range of renal damage, culminating in end-stage renal failure at an average age of 45 years and with an average survival of 3 years beyond ESRD. The various renal disorders are : glomerular hyperfiltration and then glomerulosclerosis; tubular dysfunction, especially proximal and distal hyposthenuria (a factor in enuresis); papillary necrosis, renal infarction, episodes of acute renal failure during vaso-occlusive crises; dysregulation of the renin-angiotensin system with early arterial hypertension and, more rarely, extra-membranous glomerulonephritis. In the early stages of these conditions, simple paraclinical tests can identify them before the appearance of specific clinical signs. In patients suffering from MDS, the HAS (High Authority of Health) recommends an annual check-up carried out in a Competence Centre. According to the HAS recommendations for annual surveillance, in addition to the search for other organic complications, for renal pathology, only microalbuminuria and renal ultrasound are recommended. However, as the literature shows, microalbuminuria and ultrasound only detect some of these renal disorders and at a very late stage. A large number of publications in adults and, to a lesser degree, in children, demonstrate the correlation between the frequency of acute complications of sickle cell disease (episodes of haemolysis, etc.) and the occurrence of kidney damage.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anemia, Sickle Cell

Clinical Trial Details

NCT number	NCT05211037
Study type	Interventional
Source	Centre Hospitalier Universitaire de Nice
Contact	Camille FAUDEUX, Dr
Phone	4.92.03.63.65
Email	[email protected]
Status	Not yet recruiting
Phase	N/A
Start date	February 2022
Completion date	February 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04134299` - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease	N/A
Recruiting	`NCT05087303` - Telemedicine for Children With Sickle Cell Disease	N/A
Completed	`NCT02561312` - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed	`NCT00890396` - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Recruiting	`NCT04170348` - Daily Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Recruiting	`NCT04584528` - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease	N/A
Recruiting	`NCT02286154` - Therapeutic Response Evaluation and Adherence Trial (TREAT)	N/A
Completed	`NCT02857023` - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease	N/A
Withdrawn	`NCT01925001` - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis	Phase 2
Terminated	`NCT00122980` - Stroke With Transfusions Changing to Hydroxyurea	Phase 3
Completed	`NCT00246077` - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport	N/A
Completed	`NCT00094887` - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises	Phase 2
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Terminated	`NCT04091737` - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Phase 1
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04011345` - Folic Acid Supplementation in Children With Sickle Cell Disease	N/A
Recruiting	`NCT03062501` - Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease — NEPHRO-DREPA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms